News
7h
The New Republic on MSNLaura Loomer Is Getting a Taste of Her Own MedicineAs Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...
I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second ...
Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure ...
The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...
Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Trump appeared to acknowledge in the interview that his ruthless mass deportation campaign is hurting farms, which rely on ...
The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
6d
Fintel on MSNBarclays Upgrades Sarepta Therapeutics (SRPT)Fintel reports that on July 30, 2025, Barclays upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results